Trial · NCT03412890
Adverse events66
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 66
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Relugolix Plus E2/NETA (Group A) | 6 | 163 | |
| other | Headache | Nervous system disorders | Relugolix Plus Delayed E2/NETA (Group B) | 7 | 149 | |
| other | Headache | Nervous system disorders | Placebo (Group C) | 11 | 164 | |
| other | Hot flush | Vascular disorders | Relugolix Plus E2/NETA (Group A) | 4 | 163 | |
| other | Hot flush | Vascular disorders | Relugolix Plus Delayed E2/NETA (Group B) | 0 | 149 | |
| other | Hot flush | Vascular disorders | Placebo (Group C) | 13 | 164 | |
| other | Nasopharyngitis | Infections and infestations | Relugolix Plus E2/NETA (Group A) | 10 | 163 | |
| other | Nasopharyngitis | Infections and infestations | Relugolix Plus Delayed E2/NETA (Group B) | 3 | 149 | |
| other | Nasopharyngitis | Infections and infestations | Placebo (Group C) | 8 | 164 | |
| other | Hypertension | Vascular disorders | Relugolix Plus E2/NETA (Group A) | 2 | 163 | |
| other | Hypertension | Vascular disorders | Relugolix Plus Delayed E2/NETA (Group B) | 3 | 149 | |
| other | Hypertension | Vascular disorders | Placebo (Group C) | 10 | 164 | |
| serious | Anaemia | Blood and lymphatic system disorders | Relugolix Plus E2/NETA (Group A) | 0 | 163 | |
| serious | Anaemia | Blood and lymphatic system disorders | Relugolix Plus Delayed E2/NETA (Group B) | 0 | 149 | |
| serious | Anaemia | Blood and lymphatic system disorders | Placebo (Group C) | 1 | 164 | |
| serious | Atrial fibrillation | Cardiac disorders | Relugolix Plus E2/NETA (Group A) | 0 | 163 | |
| serious | Atrial fibrillation | Cardiac disorders | Relugolix Plus Delayed E2/NETA (Group B) | 0 | 149 | |
| serious | Atrial fibrillation | Cardiac disorders | Placebo (Group C) | 1 | 164 | |
| serious | Cholecystitis | Hepatobiliary disorders | Relugolix Plus E2/NETA (Group A) | 0 | 163 | |
| serious | Cholecystitis | Hepatobiliary disorders | Relugolix Plus Delayed E2/NETA (Group B) | 1 | 149 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03412890/events